Roth Capital Confident in Full Sarilumab Approval; Affirms Regeneron (REGN) at 'Buy'
Tweet Send to a Friend
Roth Capital affirms Regeneron Pharma (Nasdaq: REGN) at Buy with a price target of $520 following news that the company ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
